Anxiety Disorders And Depression Treatment Global Market Report 2025

The anxiety disorders and depression treatment market size has grown strongly in recent years. It will grow from $14.06 billion in 2024 to $14.83 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth during the historic period can be attributed to factors such as the rising prevalence of anxiety disorders and depression, increased awareness of mental health issues, greater acceptance of mental health treatment, the expanding pipeline of new psychiatric drugs, and growing investment in mental health research.

The anxiety disorders and depression treatment market size is expected to see strong growth in the next few years. It will grow to $18.17 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth during the forecast period can be attributed to government initiatives supporting mental health care, increasing stress levels in modern society, broader insurance coverage for mental health treatments, a rise in work-related stress and burnout, and the expansion of telemedicine and online therapy services. Key trends in the forecast period include advancements in pharmacological treatments, improvements in diagnostic tools and techniques, the emergence of digital mental health platforms and apps, progress in psychotherapy techniques, and the development of innovative antidepressants with fewer side effects.

The growing prevalence of mental health disorders is expected to drive the expansion of the anxiety disorders and depression treatment market in the coming years. Mental health disorders affect a person’s thinking, emotions, behavior, or mood, often disrupting daily life. Increasing societal stress, including economic instability and constant social media connectivity, contributes to the rise in mental health disorders by amplifying feelings of anxiety and depression. Addressing anxiety and depression is essential for managing mental health disorders, as effectively treating these underlying conditions can significantly reduce the impact of related issues, leading to improved overall well-being and daily functioning. For example, a report published by the National Health Service in November 2023 revealed that 20.3% of children aged eight to sixteen were suspected to have a mental illness in 2023. Additionally, 21.7% of individuals aged 20 to 25 and 23.3% of those aged 17 to 19 were affected. Thus, the rising prevalence of mental health disorders is set to propel the growth of the anxiety disorders and depression treatment market.

Leading companies in the anxiety disorders and depression treatment market are increasingly focusing on developing advanced solutions, such as transcranial magnetic stimulation (TMS) therapy, to provide drug-free treatment options. TMS therapy is a non-invasive procedure that uses magnetic pulses to target specific areas of the brain, helping to alleviate symptoms of depression and other mental health conditions. For example, in March 2024, Neuronetics Inc., a US-based medical device company, announced that the US Food and Drug Administration (FDA) had granted clearance for NeuroStar Advanced Therapy as an adjunct treatment for major depressive disorder (MDD) in adolescents aged 15-21. This marks the first and only FDA-approved TMS therapy for this age group, and it represents the fourth approved use for NeuroStar. The platform demonstrated key data on the safety and efficacy of the treatment for adolescents, with 78% of the 1,169 adolescents analyzed showing a significant reduction in the severity of their depression symptoms.

In April 2025, Johnson & Johnson, a US-based pharmaceutical company, acquired Intra-Cellular Therapies for an undisclosed amount. This acquisition bolsters Johnson & Johnson’s neuroscience division by adding CAPLYTA (lumateperone), a treatment for schizophrenia and bipolar depression, to its portfolio, along with a promising pipeline for other neuropsychiatric and neurodegenerative disorders. Intra-Cellular Therapies is a US-based company specializing in depression medications.

Major players in the anxiety disorders and depression treatment market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Alkermes plc, Relmada Therapeutics Inc., Headspace Health, COMPASS Pathways plc, Talkspace Inc., Ginger, Axsome Therapeutics Inc., Mind Medicine Inc., Woebot Health Inc., Sage Therapeutics Inc., Happify Health, and Atai Life Sciences N.V.

North America was the largest region in the anxiety disorders and depression treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anxiety disorders and depression treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anxiety disorders and depression treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Anxiety disorders and depression treatment refers to the various medical, psychological, and lifestyle interventions used to manage and alleviate the symptoms of anxiety and depressive disorders. The goal of these treatments is to improve patients’ mental well-being, daily functioning, and overall quality of life.

The primary treatment approaches for anxiety disorders and depression include pharmacological treatment, psychotherapy, and a combination of both. Pharmacological treatment involves the use of medications to manage symptoms of anxiety and depression. It is utilized for various conditions such as obsessive-compulsive disorder, major depressive disorder, phobias, and others, affecting adults, adolescents, and children, and is distributed through hospital pharmacies, retail pharmacies, and other channels.

The anxiety disorders and depression treatment market research report is one of a series of new reports that provides anxiety disorders and depression treatment market statistics, including anxiety disorders and depression treatment industry global market size, regional shares, competitors with a anxiety disorders and depression treatment market share, detailed anxiety disorders and depression treatment market segments, market trends and opportunities, and any further data you may need to thrive in the anxiety disorders and depression treatment industry. This anxiety disorders and depression treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anxiety disorders and depression treatment market consists of revenues earned by entities by providing services such as medication management, online counseling, crisis intervention services, and behavioral health coaching. The market value includes the value of related goods sold by the service provider or included within the service offering. The anxiety disorders and depression treatment market also includes sales of mood stabilizers, psychotherapy apps, nutritional supplements, and mental health wearables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.